The development of lymphatic mapping and selective lymphadenectomy: a historical perspective -- Role of lymphoscintigraphy for selective sentinel lymphadenectomy -- Selective sentinel lymphadenectomy for malignant melanoma, merkel cell carcinoma, and squamous cell carcinoma -- Selective sentinel lymphadenectomy for breast cancer -- Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls -- Sentinel lymph node mapping in esophageal and gastric cancer -- Sentinel lymph node mapping in lung cancer -- Lymphatic mapping and sentinel lymphadenectomy in urology -- Selective sentinel lymphadenectomy for gynecologic cancer -- Selective sentinel lymphadenectomy for head and ncek squamous cell carcinoma -- Accurate evaluation of nodal tissues for the presence of tumor is central to the sentinel node approach -- Molecular diagnosis of micrometastasis in the sentinel lymph node -- Credentialing of nuclear medicine physicians, surgeons, and pathologists as a multidisciplinary team for selective sentinel lymphadenectomy -- Selective sentinel lymphadenectomy: progress to date and prospects for the future
Summary
In human solid cancer, the lymph node (LN) status is the most important prognostic indicator for the clinical outcome of patients. Various developments in the sentinel lymph node (SLN) concept and technology have resulted in the application of this revolutionary approach to define the draining or SLN to which the cancer may have metastasized
